The Prevalence and Impact of Neurologic Disease in Cancer
Reference32 articles.
1. Gilbert M, Armstrong T, Meyers C. Issues in assessing and interpreting quality of life in patients with malignant glioma. Semin Oncol 2000; 27 (3 Suppl 6): 20–26.
2. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 2000; 18 (3): 646–650.
3. Osoba D, Aaronson NK, Muller M et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol 1997; 34 (3): 263–278.
4. Driesse MJ, Esandi MC, Kros JM et al. Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity. Gene Ther 2000; 7 (16): 1401–1409.
5. Okada H, Pollack IF, Lotze MT et al. Gene therapy of malignant gliomas: a phase I study of IL-4-HS V-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther 2000; 11 (4): 637–653.